LN) has terminated its European licensing pact for skin medicine brodalumab with Canadian drugmaker Valeant Pharmaceuticals International Inc. (VRX. The British pharmaceutical giant said Friday that it had mutually agreed to terminate the European licensing pact... T) and has instead granted the license to Danish firm LEO Pharma A/S, in a bid to further broaden the launch market for the experimental drug. LONDON—AstraZeneca PLC (AZN.

Source: Wall Street Journal July 01, 2016 10:41 UTC